Skip to main content
SpringerLink
Log in
Book cover

Hypertension and Stroke pp 159–171Cite as

Recurrent Stroke Prevention II: Angiotensin Receptor Blockers—The LIFE, MOSES, PRoFESS, and Other Trials

  • Chapter
  • First Online:

  • 2298 Accesses

Part of the book series: Clinical Hypertension and Vascular Diseases ((CHVD))

Abstract

Elevated blood pressure is an important modifiable risk factor for stroke. Numerous large randomized clinical trials have demonstrated that lowering blood pressure prevents first and recurrent stroke, and that to a large extent, the degree of blood pressure reduction is a major determinant of the degree of risk reduction. An issue that is often debated is whether certain antihypertensive classes such as angiotensin receptor blockers (ARBs) have unique “stroke or cardiovascular preventive” properties independent of blood pressure reduction. In this chapter we will review the pharmacology and clinical effects of ARBs on primary and secondary stroke prevention as well as a variety of other clinical conditions including hypertension, diabetes mellitus, chronic kidney disease, cardiovascular disease, atrial fibrillation, and vascular cognitive impairment.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

ACCESS:

Acute Candesartan Cilextil Therapy in Stroke Survivors

CHARM:

Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity

DETAIL:

Diabetics Exposed to Telmisartan and Enalapril

HOPE:

Heart Outcomes Prevention Evaluation

IDNT:

Irbesartan in Diabetic Nephropathy Trial

IRMA II:

Irbesartan Reduction of Microalbuminuria

LIFE:

Losartan Intervention for Endpoint Reduction in Hypertension Study

MARVAL:

Microalbuminuria Reduction with valsartan

MOSES:

Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Stroke Prevention

ONTARGET:

Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

PRoFESS:

Prevention Regimen for Effectively Avoiding Second Strokes

RENAAL:

Reduction of End-Points in Non-Insulin Dependant Diabetes Mellitus with the Angiotensin II Antagonist Losaratan

TRANSCEND:

Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease

VAL-HeFT:

valsartan Heart Failure Trial

VALIANT:

valsartan in Acute Myocardial Infarction Trial

VALUE:

valsartan Antihypertensive Long-Term Use Evaluation

References

  1. Basile J, Toth PP. Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. South Med J. 2009;102:S1–12.

    Google Scholar 

  2. Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med. 2008;121:656–63.

    Article  Google Scholar 

  3. Weber MA. Angiotensin receptor blockers. In: Hypertension primer. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. pp. 461–4.

    Google Scholar 

  4. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.

    Article  CAS  PubMed  Google Scholar 

  5. ONTARGET Investigators. Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.

    Google Scholar 

  6. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.

    Google Scholar 

  7. Telmisartan Randomised Assessment Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Yusuf S, Teo K, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–83.

    Article  Google Scholar 

  8. Ripley TL, Harrison D. The power to TRANSCEND. Lancet. 2008;372:1128–30.

    Article  Google Scholar 

  9. Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218–26.

    Article  Google Scholar 

  10. Gorelick PB. The main outcomes of the MOSES study. Hosp Pharm Eur. Sep/Oct 2005:60–1.

    Google Scholar 

  11. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–37.

    Article  Google Scholar 

  12. Aiyagari V, Gorelick PB. Management of blood pressure for acute and recurrent stroke. Stroke. 2009;40:2251–6.

    Article  Google Scholar 

  13. Schrader J, Luders S, Kulschewski A, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34:1699–703.

    Article  Google Scholar 

  14. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.

    Article  Google Scholar 

  15. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.

    Article  Google Scholar 

  16. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.

    Article  Google Scholar 

  17. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362:772–6.

    Article  Google Scholar 

  18. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet. 2003;362:767–71.

    Google Scholar 

  19. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.

    Article  Google Scholar 

  20. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

    Article  Google Scholar 

  21. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.

    Article  Google Scholar 

  22. Viberti G, Wheeldon NM. Microalbuminuria Reduction With Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672–8.

    Article  Google Scholar 

  23. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.

    Article  Google Scholar 

  24. Blood Pressure Lowering Treatment Trialists’ Collaboration. Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121–3.

    Article  Google Scholar 

  25. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.

    Article  Google Scholar 

  26. Donnan GA, Davis SM. Angiotensin receptor blockers and stroke therapy: it is all about the blood pressure. Stroke. 2009;40:3163.

    Article  PubMed  Google Scholar 

  27. Gillis AM. Angiotensin-receptor blockers for prevention of atrial fibrillation – a matter of timing or target? N Engl J Med. 2009;360:1669–71.

    Article  Google Scholar 

  28. Gorelick PB. Risk factors for vascular dementia and alzheimer disease. Stroke. 2004;35:2620–22.

    Article  Google Scholar 

  29. Gorelick PB, William M. Feinberg lecture: cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke. 2005;36:875–9.

    Article  Google Scholar 

  30. Gorelick PB. Can we save the brain from the ravages of midlife cardiovascular risk factors? Neurology. 1999;52:1114–15.

    CAS  PubMed  Google Scholar 

  31. Gorelick PB, Erkinjuntti T, Hofman A, Rocca WA, Skoog I, Winblad B. Prevention of vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S131–9.

    Article  PubMed  Google Scholar 

  32. Gorelick PB, Bowler JV. Advances in vascular cognitive impairment 2007. Stroke. 2008;39:279–82.

    Article  PubMed  Google Scholar 

  33. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol. 2004;43:1343–7.

    Article  PubMed  Google Scholar 

  34. Sink KM, Leng X, Williamson J, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the cardiovascular health study. Arch Intern Med. 2009;169:1195–202.

    Article  CAS  PubMed  Google Scholar 

  35. Birns J, Kalra L. Cognitive function and hypertension. J Hum Hypertens. 2009;23:86–96.

    Article  CAS  PubMed  Google Scholar 

  36. Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci. 2005;229–30:151–5.

    Google Scholar 

  37. Skoog I, Lithell H, Hansson L, et al. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: study on cognition and prognosis in the elderly (SCOPE). Am J Hypertens. 2005;18:1052–9.

    Article  CAS  PubMed  Google Scholar 

  38. Diener HC, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the prevention regimen for effectively avoiding second strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7:875–84.

    Article  CAS  PubMed  Google Scholar 

  39. Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens. 1999;12:1130–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology and Rehabilitation, College of Medicine at Chicago, University of Illinois, Chicago, IL, USA

    Venkatesh Aiyagari MBBS, DM & Philip B. Gorelick MD MPH, FACP

Authors
  1. Venkatesh Aiyagari MBBS, DM
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip B. Gorelick MD MPH, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Venkatesh Aiyagari MBBS, DM .

Editor information

Editors and Affiliations

  1. College of Medicine, Dept. Neurology, University of Illinois, 912 S. Wood Street Room 855 N, Chicago, 60612, Illinois, USA

    Venkatesh Aiyagari

  2. University of Illinois, Department of Neurology and Rehabilitati, College of Medicine at Chicago, S. Wood St 912, Chicago, 60612, Illinois, USA

    Philip B. Gorelick

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Aiyagari, V., Gorelick, P.B. (2011). Recurrent Stroke Prevention II: Angiotensin Receptor Blockers—The LIFE, MOSES, PRoFESS, and Other Trials. In: Aiyagari, V., Gorelick, P. (eds) Hypertension and Stroke. Clinical Hypertension and Vascular Diseases. Humana Press. https://doi.org/10.1007/978-1-60761-010-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-010-6_10

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-009-0

  • Online ISBN: 978-1-60761-010-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation